Jeff Ajer

Jeff Ajer

DirectoratBiomarin Pharmaceutical· In proxies 2021–2023

Pay in FY2023-7% from the year before · Biomarin Pharmaceutical stock -6.8% the same year

Jeff Ajer was paid $5.1M in FY2023 (Dec), down 7%. Biomarin Pharmaceutical stock fell 6.8% that year.

Pay$100 in the stock at the end of FY20 → $110
Pay is from the Summary Compensation Table of each Biomarin Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Nektar TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Biomarin PharmaceuticalPublic company · 5 yr
    • Executive Vice President, Chief Commercial Officer2021 – Present · 5 yrStock in role -37%
  3. True North TherapeuticsPublic company
    • Director? – 2017No stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Nektar TherapeuticsDirector · 6 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?